Lapazio Lucia, Braun Monika, Grandien Kaj
Sanofi-Aventis Deutschland GmbH, R&D, Biologics Research, Industriepark Hoechst, 65926 Frankfurt am Main, Germany.
Medigene, Lochhamer Str. 11, Martinsried, 82152 Planegg, Germany.
Vaccines (Basel). 2021 Sep 22;9(10):1053. doi: 10.3390/vaccines9101053.
CD8 and CD4 T cell activation are both required for a strong and long-lasting T cell immune response. Endogenously expressed proteins are readily processed by the MHC class I antigen presentation pathway, enabling activation of CD8+ T cells. However, the MHC class II antigen presentation pathway, necessary for CD4+ T cell activation, is generally not sufficiently accessible to endogenously expressed proteins, limiting the efficiency of mRNA- or DNA-based vaccines. In the current study, we have evaluated the feasibility of using antigen sequences fused to sequences derived from the H2-M and H2-O proteins, two complexes known to participate in MHC class II antigen processing, for the enhancement of CD4 T-cell activation. We analyzed T cell activation after genetic immunization with mRNA-encoding fusion proteins with the model antigen ovalbumin and sequences derived from H2-M or H2-O. Our results show that H2-M- or H2-O-derived sequences robustly improve antigen-specific CD4 T-cell activation when fused to the antigen of interest and suggest that the approach could be used to improve the efficiency of mRNA- or DNA-based vaccines.
强大且持久的T细胞免疫反应需要CD8和CD4 T细胞的激活。内源性表达的蛋白质很容易通过MHC I类抗原呈递途径进行加工,从而激活CD8+ T细胞。然而,CD4+ T细胞激活所必需的MHC II类抗原呈递途径,通常对内源性表达的蛋白质不够容易接近,这限制了基于mRNA或DNA的疫苗的效率。在本研究中,我们评估了使用与源自H2-M和H2-O蛋白的序列融合的抗原序列来增强CD4 T细胞激活的可行性,这两种复合物已知参与MHC II类抗原加工。我们分析了用编码与模型抗原卵清蛋白以及源自H2-M或H2-O的序列融合的蛋白质的mRNA进行基因免疫后的T细胞激活情况。我们的结果表明,当与感兴趣的抗原融合时,源自H2-M或H2-O的序列能有力地改善抗原特异性CD4 T细胞的激活,并表明该方法可用于提高基于mRNA或DNA的疫苗的效率。